These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Effects of rivaroxaban on routine coagulation screening tests using commonly used reagents. Platton S; Bowles L; MacCallum P Br J Haematol; 2017 Nov; 179(3):511-513. PubMed ID: 27392166 [No Abstract] [Full Text] [Related]
3. Low molecular weight heparin anti-Xa assays can identify patients with clinically important apixaban and rivaroxaban drug levels. Mithoowani S; Moffat KA; Gupta A; Carlino SA; Crowther MA Thromb Res; 2022 Jul; 215():1-4. PubMed ID: 35580465 [No Abstract] [Full Text] [Related]
4. Evaluation of point-of-care coagulation tests as alternatives to anti-Xa activity for monitoring the anticoagulant effects of rivaroxaban in healthy dogs. Lynch AM; Ruterbories LK; Griffith EH; Hanel RM; Stablein AP; Brooks MB J Vet Emerg Crit Care (San Antonio); 2021 Jan; 31(1):18-24. PubMed ID: 33118685 [TBL] [Abstract][Full Text] [Related]
5. Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay. Schenk B; Würtinger P; Streif W; Sturm W; Fries D; Bachler M Br J Anaesth; 2016 Nov; 117(5):583-591. PubMed ID: 27623677 [TBL] [Abstract][Full Text] [Related]
6. Measurement and reversal of the direct oral anticoagulants. Samuelson BT; Cuker A Blood Rev; 2017 Jan; 31(1):77-84. PubMed ID: 27625113 [TBL] [Abstract][Full Text] [Related]
7. Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study. Testa S; Legnani C; Tripodi A; Paoletti O; Pengo V; Abbate R; Bassi L; Carraro P; Cini M; Paniccia R; Poli D; Palareti G J Thromb Haemost; 2016 Nov; 14(11):2194-2201. PubMed ID: 27566988 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban. Slavik L; Jacova J; Friedecky D; Ulehlova J; Tauber Z; Prochazkova J; Hlusi A; Palova M Clin Appl Thromb Hemost; 2019; 25():1076029619872556. PubMed ID: 31523979 [TBL] [Abstract][Full Text] [Related]
9. Concomitant assessment of rivaroxaban concentration and its impact on thrombin generation. Bloemen S; Zwaveling S; Mullier F; Douxfils J Thromb Res; 2019 Dec; 184():8-15. PubMed ID: 31677449 [TBL] [Abstract][Full Text] [Related]
10. Comment on the use of computational models to study the effect of apixaban and rivaroxaban on thrombin generation. Kremers RM; Wagenvoord RJ; Hemker HC Thromb Haemost; 2016 Apr; 115(4):869-70. PubMed ID: 26467386 [No Abstract] [Full Text] [Related]
11. Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors. Beyer J; Trujillo T; Fisher S; Ko A; Lind SE; Kiser TH Clin Appl Thromb Hemost; 2016 Jul; 22(5):423-8. PubMed ID: 26842561 [TBL] [Abstract][Full Text] [Related]
12. Application of Activators Ecarin and Factor Xa in Thrombelastography for Measurement of Anticoagulant Effect of Direct Oral Anticoagulants Using TEG 5000. Artang R; Brod C; Nielsen JD Semin Thromb Hemost; 2022 Oct; 48(7):808-813. PubMed ID: 36174600 [TBL] [Abstract][Full Text] [Related]
13. Monitoring DOACs with a Novel Dielectric Microsensor: A Clinical Study. Maji D; Opneja A; Suster MA; Bane KL; Wilson BM; Mohseni P; Stavrou EX Thromb Haemost; 2021 Jan; 121(1):58-69. PubMed ID: 32877954 [TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban versus warfarin in the prevention of post-thrombotic syndrome. Jeraj L; Jezovnik MK; Poredos P Thromb Res; 2017 Sep; 157():46-48. PubMed ID: 28692839 [TBL] [Abstract][Full Text] [Related]
15. Laboratory testing for lupus anticoagulant (LA) in patients taking direct oral anticoagulants (DOACs): potential for false positives and false negatives. Favaloro EJ; Mohammed S; Curnow J; Pasalic L Pathology; 2019 Apr; 51(3):292-300. PubMed ID: 30665674 [TBL] [Abstract][Full Text] [Related]
16. The effect of DOAC-Stop on lupus anticoagulant testing in plasma samples of venous thromboembolism patients receiving direct oral anticoagulants. Ząbczyk M; Kopytek M; Natorska J; Undas A Clin Chem Lab Med; 2019 Aug; 57(9):1374-1381. PubMed ID: 30763261 [TBL] [Abstract][Full Text] [Related]
17. Novel assay based on diluted prothrombin time reflects anticoagulant effects of direct oral factor Xa inhibitors: Results of multicenter study in Japan. Ieko M; Ohmura K; Naito S; Yoshida M; Sakuma I; Ikeda K; Ono S; Suzuki T; Takahashi N Thromb Res; 2020 Nov; 195():158-164. PubMed ID: 32707358 [TBL] [Abstract][Full Text] [Related]
18. The effect of contrast agents on the anticoagulant properties of oral factor Xa inhibitors. Cavlan B; Ari S; Ari H; Çamci S; Melek M; Bozat T Acta Radiol; 2023 Feb; 64(2):588-595. PubMed ID: 35296141 [TBL] [Abstract][Full Text] [Related]
19. Rivaroxaban for the treatment and prevention of thromboembolic disease. Antoniou S J Pharm Pharmacol; 2015 Aug; 67(8):1119-32. PubMed ID: 26059702 [TBL] [Abstract][Full Text] [Related]
20. [Pharmacologic and clinical characteristics of direct inhibitors of factor Xa: rivaroxaban, apixaban, edoxaban and betrixaban]. Meddahi S; Samama MM J Mal Vasc; 2014 May; 39(3):183-94. PubMed ID: 24650612 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]